Generic Vykat XR Availability
Last updated on May 7, 2025.
Vykat XR is a brand name of diazoxide choline, approved by the FDA in the following formulation(s):
VYKAT XR (diazoxide choline - tablet, extended release;oral)
-
Manufacturer: SOLENO THERAP
Approval date: March 26, 2025
Strength(s): 25MG [RLD], 75MG [RLD], 150MG [RLD]
Is there a generic version of Vykat XR available?
No. There is currently no therapeutically equivalent version of Vykat XR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vykat XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
Patent 12,178,823
Issued: December 31, 2024
Inventor(s): Cowen; Neil M.
Assignee(s): ESSENTIALIS, INC. (Redwood City, CA)Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
Patent expiration dates:
- November 12, 2035✓
- November 12, 2035
-
Salts of potassium ATP channel openers and uses thereof
Patent 7,572,789
Issued: August 11, 2009
Inventor(s): Cowen; Neil M. et al.
Assignee(s): Essentialis, Inc. (Carlsbad, CA)Provided are immediate or prolonged administration of certain salts of K.sub.ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K.sub.ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Patent expiration dates:
- December 20, 2026✓✓
- December 20, 2026
-
Salts of potassium ATP channel openers and uses thereof
Patent 7,799,777
Issued: September 21, 2010
Inventor(s): Cowen; Neil M. et al.
Assignee(s): Essentialis, Inc. (Carlsbad, CA)Provided are immediate or prolonged administration of certain salts of K.sub.ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K.sub.ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Patent expiration dates:
- March 5, 2029✓
- March 5, 2029
-
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
Patent 9,757,384
Issued: September 12, 2017
Inventor(s): Cowen; Neil M.
Assignee(s): Essentialis, Inc. (Redwood City, CA)Provided are immediate or prolonged administration of certain potassium ATP (K.sub.ATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K.sub.ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K.sub.ATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering K.sub.ATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
Patent expiration dates:
- November 12, 2035✓
- November 12, 2035
More about Vykat XR (diazoxide choline)
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
